Sun Pharma receives USFDA approval for ophthalmic solution

Sun Pharmaceutical Industries Limited has received approval for CEQUA (cyclosporine ophthalmic solution) 0.09%, from the US Food and Drug Administration (FDA). CEQUA is indicated to increase the tear production in patients that suffer from the condition of Keratoconjunctivitis sicca that is, dry eyes.

CEQUA provides the highest FDA-approved concentration of cyclosporine A (CsA) and that incorporates a nanomicellar technology. This technology uses micelles, which are gelatinous aggregates of amphipathic (both hydrophobic and hydrophilic) molecules formed at a well-defined concentration. The small size of the nanomicelles facilitates entry into corneal and conjunctival cells enabling delivery of high concentrations of CsA.

CEQUA 0.09%, for topical ophthalmic use will be commercialized in the US market by Sun Ophthalmics, which is a division of Sun Pharma’s wholly-owned subsidiary.

On Thursday, Sun Pharmaceutical Industries hit its intraday high at Rs. 618 per share and its intraday low was at Rs. 602 per share on the BSE. Its recorded 52-week high was Rs. 618 and 52-week low was Rs. 434.80 per share on the BSE.

At 12:00 hours, the stock was trading at Rs. 614 up by 2.06 per cent. Meanwhile, the Indian benchmark indices, the BSE Sensex was quoting at 37,862.47, up by 0.02 percent, and the Nifty50 was trading at 11,432, up by 0.03 per cent.